Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Alafenamide for HBV Reactivation in DLBCL/CLL
NCT03804372Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Jul 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenofovir alafenamide in hepatitis B (HBV), sponsored by GIMEMA. Started Jul 2020; status: terminated.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03804372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804372.